brillo tirzepatide Sublingual GLP-1/GIP (Tirz) Oral Drops 22% body weight Compounded Tirzepatide With B6 (Pyridoxine)

Ohkawa K, Tsukada Y, Dohzono H, Koike K, Terashima Y

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors, designed to enhance glycemic control in patients with type 2 diabetes

Both, SGLT2 inhibitors and GLP1 receptor agonists, had similar effect on MACE reduction, but SGLT2 inhibitors have far more benefits in patients with heart failure

Furthermore, the guidelines advise medical professionals to think about postponing surgeries if the patient reports significant gastrointestinal symptoms on the day of the procedure, such as pronounced nausea, vomiting, abdominal discomfort, or bloating

10.1016/j.tranon.2016.07.002 164 RobertN